Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

INFINITY PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 d423522dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies – IPI-549 with AB928 and AB122 in Triple Negative Breast Cancer and Ovarian Cancer – – IPI-549 with AB928 and Chemotherapy in Triple Negative Breast Cancer and Ovarian Cancer –     HAYWARD,…
To view the full exhibit click here

About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.